Understanding the genetic factors in neurofibromatosis type 1 tumors
Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1
['FUNDING_R01'] · UNIVERSITY OF IOWA · NIH-11031322
This study is looking at the genetic changes that happen in certain tumors for people with neurofibromatosis type 1 (NF1) to understand why some harmless tumors turn into cancerous ones, which could help find better treatments for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF IOWA (nih funded) |
| Locations | 1 site (IOWA CITY, UNITED STATES) |
| Trial ID | NIH-11031322 on ClinicalTrials.gov |
What this research studies
This research investigates the genetic changes associated with malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1 (NF1). It focuses on the INK4a/ARF/INK4b locus, which is believed to play a crucial role in the transformation of benign tumors into malignant ones. By analyzing genetic and proteomic events, the study aims to uncover why only a subset of benign plexiform neurofibromas progress to MPNSTs. The findings could lead to better understanding and potential new treatments for patients with NF1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 1, particularly those with plexiform neurofibromas.
Not a fit: Patients without neurofibromatosis type 1 or those who do not have plexiform neurofibromas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing the progression of benign tumors to malignant ones in NF1 patients.
How similar studies have performed: Previous research has shown promising results in understanding genetic factors in tumor progression, making this approach both relevant and potentially impactful.
Where this research is happening
IOWA CITY, UNITED STATES
- UNIVERSITY OF IOWA — IOWA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DODD, REBECCA D — UNIVERSITY OF IOWA
- Study coordinator: DODD, REBECCA D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug